Ethical Considerations for the Clinical Oncologist in an Era of Oncology Drug Shortages
dc.contributor.author | Jagsi, Reshma | |
dc.contributor.author | Spence, Rebecca | |
dc.contributor.author | Rathmell, W. Kimryn | |
dc.contributor.author | Bradbury, Angela | |
dc.contributor.author | Peppercorn, Jeffrey | |
dc.contributor.author | Grubbs, Stephen | |
dc.contributor.author | Moy, Beverly | |
dc.date.accessioned | 2017-12-15T16:49:11Z | |
dc.date.available | 2017-12-15T16:49:11Z | |
dc.date.issued | 2014-02 | |
dc.identifier.citation | Jagsi, Reshma; Spence, Rebecca; Rathmell, W. Kimryn; Bradbury, Angela; Peppercorn, Jeffrey; Grubbs, Stephen; Moy, Beverly (2014). "Ethical Considerations for the Clinical Oncologist in an Era of Oncology Drug Shortages." The Oncologist 19(2): 186-192. | |
dc.identifier.issn | 1083-7159 | |
dc.identifier.issn | 1549-490X | |
dc.identifier.uri | https://hdl.handle.net/2027.42/140043 | |
dc.publisher | AlphaMed Press | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | Recommendations | |
dc.subject.other | Shortage | |
dc.subject.other | Drug | |
dc.subject.other | Oncology | |
dc.subject.other | Ethics | |
dc.subject.other | Policy | |
dc.title | Ethical Considerations for the Clinical Oncologist in an Era of Oncology Drug Shortages | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Hematology and Oncology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA; | |
dc.contributor.affiliationother | Massachusetts General Hospital, Boston, Massachusetts, USA | |
dc.contributor.affiliationother | Medical Oncology Hematology Consultants, Newark, Delaware, USA; | |
dc.contributor.affiliationother | Duke University, Durham, North Carolina, USA; | |
dc.contributor.affiliationother | University of Pennsylvania, Philadelphia, Pennsylvania USA; | |
dc.contributor.affiliationother | University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; | |
dc.contributor.affiliationother | American Society of Clinical Oncology, Alexandria, Virginia, USA; | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/140043/1/onco0186.pdf | |
dc.identifier.doi | 10.1634/theoncologist.2013-0301 | |
dc.identifier.source | The Oncologist | |
dc.identifier.citedreference | R Jagsi, TF DeLaney, K Donelan. Real‐time rationing of scarce resources: The Northeast Proton Therapy Center experience. J Clin Oncol. 2004; 22: 2246 – 2250. | |
dc.identifier.citedreference | S Hoffman. The drugs stop here: A public health framework to address the drug shortage crisis. Food Drug Law J. 2012; 67: 1 – 22. | |
dc.identifier.citedreference | R Kaakeh, BV Sweet, C Reilly. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm. 2011; 68: 1811 – 1819. | |
dc.identifier.citedreference | A McBride, LM Holle, C Westendorf. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm. 2013; 70: 609 – 617. | |
dc.identifier.citedreference | K Haninger, A Jessup, K. Koehler. Economic analysis of the causes of drug shortages (ASPE issue brief). Washington, DC: United States Department of Health and Human Services. 2011, Available at http://www.aspe.hhs.gov/sp/reports/2011/drugshortages/ib.shtml. | |
dc.identifier.citedreference | BA Chabner. Drug shortages—a critical challenge for the generic‐drug market. N Engl J Med. 2011; 365: 2147 – 2149. | |
dc.identifier.citedreference | Jacobson M, Alpert A, Duarte F. Prescription drug shortages: Reconsidering the role of Medicare payment policies. Available at http://healthaffairs.org/blog/2012/05/29/prescription‐drug‐shortages‐reconsidering‐the‐role‐of‐medicare‐payment‐policies. | |
dc.identifier.citedreference | Office of the Press Secretary. We can’t wait: Obama Administration takes action to reduce prescription drug shortages, fight price gouging [press release]. Washington, DC: White House. 2011, Available at http://www.whitehouse.gov/the‐press‐office/2011/10/31/we‐can‐t‐wait‐obama‐administration‐takes‐action‐reduce‐prescription‐drug. | |
dc.identifier.citedreference | U.S. Food and Drug Administration. FDA acts to bolster supply of critically needed cancer drugs [press release], 02/2012 update. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm292658.htm. | |
dc.identifier.citedreference | U.S. Food and Drug Administration. FDA approval of generic version of cancer drug Doxil is expected to help resolve shortage. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337872.htm. | |
dc.identifier.citedreference | U.S. Food and Drug Administration. The Food and Drug Administration Safety and Innovation Act (FDASIA), S. 3187, 2012. Available at http://www.gpo.gov/fdsys/pkg/BILLS‐112s3187pcs/pdf/BILLS‐112s3187pcs.pdf. | |
dc.identifier.citedreference | D Callahan. Rationing: theory, politics, and passions. Hastings Cent Rep. 2011; 41: 23 – 27. | |
dc.identifier.citedreference | HJ Aaron, WB Schwartz. The Painful Prescription: Rationing Hospital Care. Washington, DC: Brookings Institution. 1984. | |
dc.identifier.citedreference | HJ Aaron, WB Schwartz. Can We Say NO? The Challenge of Rationing Health Care. Washington, DC: Brookings Institution. 2005. | |
dc.identifier.citedreference | PA Ubel. Pricing Life: Why It’s Time for Health Care Rationing. Cambridge, MA: MIT Press. 2000. | |
dc.identifier.citedreference | A Boulis, S Goold, PA Ubel. Responding to the immunoglobulin shortage: A case study. J Health Polit Policy Law. 2002; 27: 977 – 999. | |
dc.identifier.citedreference | Health Resources and Services Administration. Organ distribution: Allocation of deceased kidneys, 9/12 update. Available at http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_7.pdf. | |
dc.identifier.citedreference | BH Scribner. Lasker Clinical Medicine Research Award. Medical dilemmas: The old is new. Nat Med. 2002; 8: 1066 – 1067. | |
dc.identifier.citedreference | M Strosberg, J Wiener, R Baker, eds. Rationing America’s Medical Care: The Oregon Plan and Beyond. Washington, DC: Brookings Institution. 1992. | |
dc.identifier.citedreference | G Calabresi, P Bobbitt. Tragic Choices. New York, NY: W.W. Norton. 1978. | |
dc.identifier.citedreference | MG Bloche. Clinical loyalties and the social purposes of medicine. JAMA. 1999; 281: 268 – 274. | |
dc.identifier.citedreference | PA Ubel, RM Arnold. The unbearable rightness of bedside rationing. Physician duties in a climate of cost containment. Arch Intern Med. 1995; 155: 1837 – 1842. | |
dc.identifier.citedreference | N Daniels, J Sabin. The ethics of accountability in managed care reform. Health Aff (Millwood). 1998; 17: 50 – 64. | |
dc.identifier.citedreference | Rosoff PM. Unpredictable drug shortages: An ethical framework for short‐term rationing in hospitals. Am J Bioeth. 2012; 12: 1 – 9. | |
dc.identifier.citedreference | PM Rosoff, KR Patel, A Scates. Coping with critical drug shortages: An ethical approach for allocating scarce resources in hospitals. Arch Intern Med. 2012; 172: 1494 – 1499. | |
dc.identifier.citedreference | ML Burda. Beyond the framework. Am J Bioeth. 2012; 12: 11 – 13. | |
dc.identifier.citedreference | A Goodman. The tensions and challenges of unpredictable drug shortages. Am J Bioeth. 2012; 12: 20 – 22. | |
dc.identifier.citedreference | R Bamford, CD Brewer, B Bucknell. A paradoxical ethical framework for unpredictable drug shortages. Am J Bioeth. 2012; 12: 16 – 18. | |
dc.identifier.citedreference | JJ Caro, CN Coleman, A Knebel. Unaltered ethical standards for individual physicians in the face of drastically reduced resources resulting from an improvised nuclear device event. J Clin Ethics. 2011; 22: 33 – 41. | |
dc.identifier.citedreference | AK Thompson, K Faith, JL Gibson. Pandemic influenza preparedness: An ethical framework to guide decision‐making. BMC Med Ethics. 2006; 7: E12. | |
dc.identifier.citedreference | JL Gibson, S Bean, P Chidwick. Ethical framework for resource allocation during a drug supply shortage. Healthc Q. 2012; 15: 26 – 35. | |
dc.identifier.citedreference | J Peppercorn, A Armstrong, DW Zaas. Rationing in urologic oncology: Lessons from sipuleucel‐T for advanced prostate cancer. Urol Oncol. 2013; 31: 1079 – 1084. | |
dc.identifier.citedreference | MP Link, K Hagerty, HM Kantarjian. Chemotherapy drug shortages in the United States: Genesis and potential solutions. J Clin Oncol. 2012; 30: 692 – 694. | |
dc.identifier.citedreference | ML Metzger, A Billett, MP Link. The impact of drug shortages on children with cancer—The example of mechlorethamine. N Engl J Med. 2012; 367: 2461 – 2463. | |
dc.identifier.citedreference | J Valgus, EA Singer, SR Berry. Ethical challenges: Managing oncology drug shortages. J Oncol Pract. 2013; 9: e21 – e23. | |
dc.identifier.citedreference | E Blume. Investigators seek to increase taxol supply. J Natl Cancer Inst. 1989; 81: 1122 – 1123. | |
dc.identifier.citedreference | N Landis. Provisional observations on drug product shortages: Effects, causes, and potential solutions. Am J Health Syst Pharm. 2002; 59: 2173 – 2182, Available at http://www.ashp.org/s_ashp/docs/files/DShort_11b‐SF‐Witmer.pdf. | |
dc.identifier.citedreference | Park A. Inside America’s drug shortage. Time, March 2012. Available at http://healthland.time.com/2012/03/19/where‐have‐all‐our‐drugs‐gone/. | |
dc.identifier.citedreference | U.S. Food and Drug Administration, Center for Drugs and Evaluation Research Drug Shortage Program. Frequently asked questions about drug shortages. Available at http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050796.htm#q1. | |
dc.identifier.citedreference | ER Fox, A Birt, KB James, ASHP Expert Panel on Drug Product Shortages. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm. 2009; 66: 1399 – 1406. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.